Targeting Notch3 to treat multiple myeloma
Official title: Targeting Notch3 for the treatment of multiple myeloma
Funded at Univ of Arkansas for Med Scis · NIH-10892640 · Data updated 2026-11-12
This study is looking at how blocking a protein called Notch3 might help people with multiple myeloma by slowing down tumor growth and reducing bone problems, with the hope of making current treatments work better and cause fewer side effects.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $39,248 |
| NIH project number | 5F31CA284655-02 |
| Project ID | NIH-10892640 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with multiple myeloma who are seeking new treatment options.
✕Less likely to help
Patients with other types of cancers or those who do not have multiple myeloma may not benefit from this research.
What this research studies
This research investigates the role of Notch3, a specific receptor involved in cell communication, in the treatment of multiple myeloma, a type of blood cancer. The study aims to understand how inhibiting Notch3 can reduce tumor growth and bone disease associated with multiple myeloma, which is known for its high relapse rates and resistance to existing therapies. By focusing on Notch3, the researchers hope to improve the effectiveness of current treatments and reduce side effects. The approach includes evaluating the impact of Notch3 inhibition on tumor growth and patient responses to standard therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for multiple myeloma, improving patient outcomes and quality of life.
How similar studies have gone: Previous research has shown promise in targeting Notch signaling in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
-
Univ of Arkansas for Med Scis
Little Rock, United States Active
Researchers
- Principal investigator: Sabol, Hayley — Univ of Arkansas for Med Scis
- Study coordinator: Sabol, Hayley
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.